Premium
Evolution of hiperreflective points after intravitreal dexamethasone implant injection in patients with macular edema associated with retinal vein occlusion
Author(s) -
Almenara Michelena C.,
Ascaso F.J.,
Idoate A.,
Caramello C.M.,
Sánchez J.I.,
Berniolles J.,
Cristobal J.
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2015.0712
Subject(s) - medicine , retinal vein , macular edema , dexamethasone , ophthalmology , visual acuity , occlusion , implant , edema , retinal , central retinal vein occlusion , optical coherence tomography , surgery
Purpose To analyse the evolution of macular hyperreflective points ( HRP ) detected by spectral‐domain optical coherence tomography ( SD ‐ OCT ) in eyes with macular edema secondary to retinal vein occlusion ( RVO ), following treatment with intravitreal dexamethasone implant (Ozurdex ® ). Methods Retrospective observational study of 45 consecutive cases of RVO ‐associated macular edema: 13 central RVO and 32 branch RVO treated with Ozurdex ® . The relationship between best corrected visual acuity ( BCVA ), central macular thickness ( CMT ) and the presence of HRD in SD ‐ OCT before treatment and two months post‐injection was determined. Results CMT decreased significantly following treatment (527.7 μm vs 308.3 μm, p < 0.001). Although there was a visual acuity improvement in 18 of the 45 eyes (40%), the mean BCVA difference was not statistically significant (p = 0.373). Numerous HRP were detected in 24 patients (53.3%), disappearing in 10 of them (41.7%) after corticosteroid intravitreal therapy. Conclusions Disappearance of HRP after an intravitreal dexamethasone impant would support the hypothesis that HRP could represent some inflammatory cells.